Best medication for ulcerative colitis, honestly

The 5-aminosalicylate (5-ASA) that is the first-line backbone for mild-to-moderate UC — used to induce remission in a flare AND to maintain it long-term, which is the part people miss: it is a daily maintenance drug, not a rescue you stop when symptoms ease. It works topically on the colon lining rather than suppressing the whole immune system, so it is generally well tolerated. Mesalamine is the sulfa-free 5-ASA (unlike sulfasalazine), so it usually suits people who cannot take sulfa; it is still a salicylate, so caution applies with aspirin/salicylate allergy. Rarely it inflames the kidneys, so the label has renal function checked before and periodically during treatment. When the disease is limited to the rectum or left colon, rectal mesalamine (suppository, enema or foam) delivers it straight to the inflammation, often alongside the oral form.

The original aminosalicylate: a 5-ASA molecule bonded to a sulfa carrier (sulfapyridine) that releases it in the colon. About as effective as mesalamine for mild-to-moderate UC and much cheaper, and a common pick when UC comes with inflammatory joint disease — but the sulfa part causes more side effects (nausea, headache, and a reversible drop in sperm count in men), so it is taken with folic acid. It is CONTRAINDICATED in people allergic to sulfa drugs or salicylates, and in intestinal or urinary obstruction or porphyria — all labeled contraindications. Like all 5-ASAs it is used for both inducing and maintaining remission. Rarely it causes a severe skin reaction or a fall in blood cells, so a new spreading rash, mouth sores, or fever with a sore throat needs prompt attention.

An oral JAK inhibitor — a pill rather than an infusion — for moderate-to-severe UC. Because of its risks, the FDA places it after a TNF blocker has failed or cannot be tolerated, at the lowest effective dose for the shortest time. FDA BOXED WARNING (the JAK-inhibitor class warning): serious infections including tuberculosis (screened for before starting), higher all-cause mortality, malignancy including lymphoma, major adverse cardiovascular events such as heart attack and stroke, and blood clots in the veins and lungs — the clot and cardiovascular risks are why leg swelling, chest pain or breathlessness are treated urgently on this drug. Like the biologics it suppresses immunity body-wide, so live vaccines are avoided.

A tumor-necrosis-factor (TNF) blocker for moderate-to-severe UC, or when steroids cannot be tapered without relapse — given as an intravenous infusion (a loading schedule, then every 8 weeks) and used for both inducing and maintaining remission. FDA BOXED WARNING: serious infections leading to hospitalization or death, including tuberculosis — patients are screened for latent TB and hepatitis B before starting — and malignancy, including lymphoma and rare, fatal hepatosplenic T-cell lymphoma reported mostly in adolescent and young-adult males with UC or Crohn's, most of them on a thiopurine at the same time. Because it suppresses the immune system body-wide, live vaccines are avoided and any fever or infection is taken seriously.

A gut-selective biologic: it blocks alpha4beta7 integrin, the traffic signal that lets inflammatory white cells enter the gut lining, so it acts largely IN the bowel rather than suppressing immunity throughout the body. That targeted action is why it is often chosen first among the advanced drugs on safety grounds — it carries NO boxed warning. Given as an intravenous infusion (a loading schedule, then every 8 weeks; a self-injected maintenance form also exists), for both inducing and maintaining remission in moderate-to-severe UC. It can work more slowly than an anti-TNF, so it is given time to take hold. Infusion reactions can occur, and — as with any immunomodulator — vaccinations are brought up to date before starting and infections are still watched for.

A corticosteroid engineered to act on the gut and then be largely broken down by the liver on first pass, so it calms a flare with far less body-wide steroid exposure than prednisone. Uceris comes as a rectal foam for disease of the lower colon and as an oral extended-release tablet for more extensive mild-to-moderate disease. Crucially it is an INDUCTION drug only — a short course to reach remission, then stopped; steroids of any kind, gut-targeted included, are not maintenance treatment, because their risks accumulate over time. Even gut-targeted, longer or repeated use can bring steroid effects and suppress the adrenal glands, so it is tapered rather than stopped abruptly and is not stacked on top of another oral steroid. Needing steroids again and again is itself the signal to step up to a maintenance drug.